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Reduced levels of physical activity and increased levels of fatigue are commonly reported in pros-
tate cancer patients treated with androgen-deprivation therapy (ADT) (1) that in turn reduces 
functional capacity. Reductions are seen in cardiorespiratory endurance, upper and lower body 
strength and endurance, and physical components of quality of life (1–3), which lead to inhibiting 
activities of daily living. In addition to these well-established side effects, cardiovascular disease 
(CVD) risk is now being increasingly associated with ADT (4, 5). Keating et al. (6) report ADT 
use is associated with higher risks of incident diabetes, coronary heart disease, acute myocardial 
infarction, and sudden cardiac death. The increasing body of literature supports an earlier report 
indicating that CVD is the most common form of mortality in men with prostate cancer, and not 
the actual cancer itself (7).
Exercise has been shown to be effective for improving surgical outcomes, reducing symptom 
experience, managing side effects, improving psychological health, maintaining physical function, 
and reducing fat gain and muscle and bone loss in cancer patients (8) and hence has the potential 
to reduce CVD risk factors. Studies in the past have used aerobic exercise (9), resistance exercise 
(9, 10), or a combination of aerobic and resistance exercise (11). Exercise programs have also 
differed in method of delivery with some home based (12) while others are group based in a clinic 
setting (11, 13) making comparisons as to the best treatment mode of exercise difficult.
RESiSTAnCE TRAininG
Resistance exercise improves muscle strength and function and has been shown to be an effective 
intervention against sarcopenia (14). This exercise mode also leads to improvements in functional 
capacity and quality of life while reducing disability in individuals with and without CVD (15, 16). 
In prostate cancer patients undergoing treatment, studies have shown positive effects of resistance 
exercise on reducing musculoskeletal treatment side effects, decreasing fatigue, and improving 
quality of life (10, 13), despite a compromised hormonal profile (17). Segal and colleagues (10) 
had patients complete resistance exercises three times per week for 12 weeks and reported upper 
and lower body muscular fitness improvements of 42 and 32%, respectively, whereas Galvao 
et al. (13) had patients undergo resistance exercise two times per week for 20 weeks and reported 
significant improvements in upper body muscular strength (chest press 40% and seated row 
42%), lower body strength (leg press 96%), functional performance (400 m walk 7.4%, stair climb 
10.4%, and chair rise 27%), and balance (7.8%).
Improvements in muscle mass, such as those seen by Galvao et  al. (11), are important not 
only in terms of mobility and functional performance but also in terms of assisting glucose 
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disposal (18). Muscle stimulates insulin sensitivity and accounts 
for up to 80% of insulin-dependent glucose uptake (19). 
Numerous clinical studies have shown resistance training to 
lower the percentage of glycated hemoglobin and increase 
glucose disposal as well as favorably impact CVD risk factors 
in elderly individuals (20, 21). Srikanthan and Karlamangla 
(22) conducted a cross-sectional analysis of the National Health 
and Nutritional Examination Survey III data to investigate the 
possible correlation between relative muscle mass and insulin 
resistance and prediabetes. After adjusting for age, ethnicity, 
sex, and generalized and central obesity, the authors found for 
every 10% increase in skeletal muscle index (skeletal muscle 
mass relative to total body mass) was associated with an 11% 
reduction in insulin resistance and a 12% relative reduction 
in prediabetes. This correlation was stronger in non-diabetic 
patients (22) and was not just limited to the lower, sarcopenic 
end of the muscle mass distribution in the population, suggest-
ing that increases in muscle mass, even above average levels, was 
associated with additional protection against insulin resistance 
and diabetes. Given the association of insulin resistance and 
CVD, the metabolic effect of muscle mass gained as a result 
of resistance training has the ability to alter CVD risk (23), 
particularly in an ADT-treated population where reductions in 
muscle mass have previously been reported (24).
AEROBiC TRAininG
Studies employing aerobic training only interventions have pri-
marily utilized breast cancer patients, with promising outcomes 
reported in physical function, fatigue mitigation, and quality of 
life (25–27). Of the aerobic intervention studies in prostate cancer 
patients, radiotherapy has been the most common treatment 
modality (28, 29) with one study utilizing ADT-treated prostate 
cancer patients (9). Segal et al. (9) reported beneficial effects of 
the aerobic training for both fatigue mitigation and maintenance 
of aerobic fitness.
With regard to non-cancer patients, it is well established that 
cardiorespiratory fitness attenuates the mortality risk associated 
with metabolic syndrome in healthy men, independent of body 
mass (30), indicating that cardiorespiratory fitness is of greater 
importance than body mass per se. High cardiorespiratory fitness 
levels have also been found to attenuate the increased arterial 
stiffness in patients with metabolic syndrome. Increases in arte-
rial stiffness, independent of age and blood pressure, have been 
reported in men receiving ADT (31–33) highlighting the need 
for prescribed aerobic exercise programs focused on improving 
cardiorespiratory fitness to offset the metabolic related treatment 
toxicities in ADT-treated patients.
COMBinED AEROBiC AnD RESiSTAnCE 
TRAininG
Although there are studies that have investigated the effects that 
resistance training programs and aerobic training programs have 
on prostate cancer patients undergoing treatment, very few have 
utilized a combined aerobic and resistance training intervention 
with prostate cancer patients undergoing ADT. Culos-Reed et al. 
(12) were one of the first study to attempt to employ a combined 
aerobic and resistance training program in ADT-treated prostate 
cancer patients; however, the study was a low-intensity home-
based intervention and hence lacked the control of a laboratory-
based intervention. This apparent lack of control may have been 
the reason for a lack of statistically significant differences. Galvao 
et al. (11) were the first group to conduct a clinic-based supervised, 
randomized controlled study to evaluate the combined effects of 
a resistance and low volume aerobic exercise program in men 
undergoing ADT. Galvao et al. (11) reported favorable changes 
in total body and regional lean mass as well as improvements 
in muscular strength and functional performance outcomes. 
Cardiorespiratory capacity only showed borderline improve-
ment, but this was thought to be a result of the low level of aerobic 
exercise prescribed. Participants undertook 30–40 min of aerobic 
exercise per week, which is well below 150 min recommended by 
the American Heart Association for good health. However, the 
promising aspect of this study was that despite the low dose of 
aerobic exercise prescribed, borderline changes were still seen in 
cardiorespiratory capacity.
COnCLUSiOn
Given the recent attention that ADT and the associated CVD risk 
have received, it is clear that exercise interventions specifically 
targeting CVD risk outcomes are required. Previous studies have 
targeted resistance training or aerobic training alone and have 
reported positive outcomes specific to the training modality. 
What is now needed are exercise interventions that apply sound 
aerobic and resistance training principles in combination to 
prevent the development of CVD in men undergoing ADT for 
the treatment of prostate cancer.
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